HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines

Cancer Letters

Volumn 315, Issue 1, 2012, Pages 18-27

  Watanabe, Miki ^a   Sheriff, Sulaiman ^b   Lewis, Kenneth B ^a   Tinch, Stuart L ^a   Cho, Junho ^a   Balasubramaniam, Ambikaipakan ^b,c,d   Kennedy, Michael A ^a  

^a MIAMI UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AsPC 1; DNA aptamer; Gemcitabine; HMGA; Pancreatic cancer

Indexed keywords

APTAMER; DNA; GEMCITABINE; HIGH MOBILITY GROUP A PROTEIN; PHOSPHOROTHIOIC ACID;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENICITY; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DEOXYCYTIDINE; HMGA PROTEINS; HUMANS; PANCREATIC NEOPLASMS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81955161885     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.005     Document Type: Article

References (40)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Bianchi V., Borella S., Calderazzo F., Ferraro P., Chieco Bianchi L., Reichard P. Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc. Natl. Acad. Sci. USA 1994, 91:8403-8407.
3. Szekeres T., Fritzer-Szekeres M., Elford H.L. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit. Rev. Clin. Lab. Sci. 1997, 34:503-528.
4. Rocha-Lima C.M., Raez L.E. Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P&T: Peer-Rev. J. Formul. Manage. 2009, 34:554-564.
5. Laurent-Puig P., Taieb J. Lessons from tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. Curr. Opin. Oncol. 2008, 20:454-458.
6. Sharma C., Eltawil K.M., Renfrew P.D., Walsh M.J., Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J. Gastroenterol.: WJG 2011, 17:867-897.
7. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7:899-910.
8. Fedele M., Bandiera A., Chiappetta G., Battista S., Viglietto G., Manfioletti G., Casamassimi A., Santoro M., Giancotti V., Fusco A. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res. 1996, 56:1896-1901.
9. Abe N., Watanabe T., Suzuki Y., Matsumoto N., Masaki T., Mori T., Sugiyama M., Chiappetta G., Fusco A., Atomi Y. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br. J. Cancer 2003, 89:2104-2109.
10. Grosschedl R., Giese K., Pagel J. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet.: TIG 1994, 10:94-100.
11. Murua Escobar H., Soller J.T., Richter A., Meyer B., Winkler S., Bullerdiek J., Nolte I. "Best friends" sharing the HMGA1 gene: comparison of the human and canine HMGA1 to orthologous other species. J. Heredity 2005, 96:777-781.
12. Abe N., Watanabe T., Masaki T., Mori T., Sugiyama M., Uchimura H., Fujioka Y., Chiappetta G., Fusco A., Atomi Y. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res. 2000, 60:3117-3122.
13. Bustin M., Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 1996, 54:35-100.
14. Chiappetta G., Avantaggiato V., Visconti R., Fedele M., Battista S., Trapasso F., Merciai B.M., Fidanza V., Giancotti V., Santoro M., Simeone A., Fusco A. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996, 13:2439-2446.
15. Pierantoni G.M., Rinaldo C., Esposito F., Mottolese M., Soddu S., Fusco A. High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ. 2006, 13:1554-1563.
16. Liau S.S., Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2008, 14:1470-1477.
17. Watanabe S., Ueda Y., Akaboshi S.-i., Hino Y., Sekita Y., Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol. 2009, 174:854-868.
18. Liau S.S., Rocha F., Matros E., Redston M., Whang E. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008, 113:302-314.
19. Reeves R., Nissen M.S. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 1990, 265:8573-8582.
20. Beckerbauer L., Tepe J.J., Cullison J., Reeves R., Williams R.M. FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem. Biol. 2000, 7:805-812.
21. Maasch C., Vater A., Buchner K., Purschke W.G., Eulberg D., Vonhoff S., Klussmann S. Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo. J. Biol. Chem. 2010, 285:40012-40018.
22. Nielsen P.E. DNA analogues with nonphosphodiester backbones. Annu. Rev. Biophys. Biomol. Struct. 1995, 24:167-183.
23. Nimjee S.M., Rusconi C.P., Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 2005, 56:555-583.
24. Sullenger B.A., Gallardo H.F., Ungers G.E., Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990, 63:601-608.
25. Huang J., Moore J., Soffer S., Kim E., Rowe D., Manley C.A., O'Toole K., Middlesworth W., Stolar C., Yamashiro D., Kandel J. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J. Pediatr. Surg. 2001, 36:357-361.
26. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakama M., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:5855-5859.
27. Cummins L., Graff D., Beaton G., Marshall W.S., Caruthers M.H. Biochemical and physicochemical properties of phosphorodithioate DNA. Biochemistry 1996, 35:8734-8741.
28. Monia B.P., Johnston J.F., Sasmor H., Cummins L.L. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem. 1996, 271:14533-14540.
29. Reeves R. HMGA proteins: isolation, biochemical modifications, and nucleosome interactions. Methods Enzymol. 2004, 375:297-322.
30. Huth J.R., Bewley C.A., Nissen M.S., Evans J.N., Reeves R., Gronenborn A.M., Clore G.M. The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif. Nat. Struct. Biol. 1997, 4:657-665.
31. Sheriff S., Ali M., Yahya A., Haider K.H., Balasubramaniam A., Amlal H. Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line. Mol. Cancer Res.: MCR 2010, 8:604-614.
32. Strauss F., Varshavsky A. A protein binds to a satellite DNA repeat at three specific sites that would be brought into mutual proximity by DNA folding in the nucleosome. Cell 1984, 37:889-901.
33. Elton T.S., Reeves R. Purification and postsynthetic modifications of friend erythroleukemic cell high mobility group protein HMG-I. Anal. Biochem. 1986, 157:53-62.
34. Reeves R., Elton T.S., Nissen M.S., Lehn D., Johnson K.R. Posttranscriptional gene regulation and specific binding of the nonhistone protein HMG-I by the 3' untranslated region of bovine interleukin 2 cDNA. Proc. Natl. Acad. Sci. 1987, 84:6531-6535.
35. Solomon M.J., Strauss F., Varshavsky A. A mammalian high mobility group protein recognizes any stretch of six A·T base pairs in duplex DNA. Proc. Natl. Acad. Sci. USA 1986, 83:1276-1280.
36. Rajski S.R., Williams R.M. Observations on the covalent cross-linking of the binding domain (BD) of the high mobility group I/Y (HMG I/Y) proteins to DNA by FR66979. Bioorg. Med. Chem. 2000, 8:1331-1342.
37. Rajski S.R., Williams R.M. DNA cross-linking agents as antitumor drugs. Chem. Rev. 1998, 98:2723-2796.
38. Vega M.C., Garcia Saez I., Aymami J., Eritja R., Van der Marel G.A., Van Boom J.H., Rich A., Coll M. Three-dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor-groove-binding drug Hoechst 33258. Eur. J. Biochem./FEBS 1994, 222:721-726.
39. Grant M.A., Baron R.M., Macias A.A., Layne M.D., Perrella M.A., Rigby A.C. Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter. Biochem. J. 2009, 418:103-112.
40. Trapasso F., Sarti M., Cesari R., Yendamuri S., Dumon K.R., Aqeilan R.I., Pentimalli F., Infante L., Alder H., Abe N., Watanabe T., Viglietto G., Croce C.M., Fusco A. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther. 2004, 11:633-641.